Table 2 Main characteristics of individual studies included in the meta-analysis
Study | Year | Country | Cancer type | Study design | Treatment | Number of patients | Cut-off values | HR (95% CI) | Months of follow-up |
|---|---|---|---|---|---|---|---|---|---|
Overall survival (OS) | |||||||||
 Cai [18] | 2017 | China | RCC | Retrospective | Target therapy | 178 | 51.62 | 1.658 (1.04–2.641) | 22 months median |
 Peng [25] | 2017 | China | BC | Retrospective | RC | 516 | 46.025/47.2 | 1.668 (1.147–2.425) | 37 months median |
 Miyake [24] | 2017 | Japan | BC | Retrospective | RC | 117 | 50 | 1.70 (0.80–3.30) | 22 months median |
 Huang [26] | 2017 | China | UTUC | Retrospective | RNU | 425 | 46.78 | 1.74 (1.20–2.53) | 38.5 months median |
 Fan [28] | 2017 | China | PC | Retrospective | Target therapy | 112 | 50.5 | 3.80 (1.00–13.9) | 20.2 months median |
 Broggi [17] | 2016 | American | RCC | Retrospective | Nephrectomy | 341 | 44.7 | 1.73 (1.09–2.76) | NR |
 Kwon [21] | 2017 | Korea | RCC | Retrospective | Target therapy | 125 | 41 | 1.96 (1.16–3.33) | 45.3 months median |
 Peng [22] | 2017 | China | RCC | Retrospective | Nephrectomy | 1360 | 47.625/47.775 | 1.645 (1.153–2.348) | 67 months median |
 Jeon [20] | 2016 | Korea | RCC | Retrospective | PN, RN | 1437 | 51 | 1.50 (1.09–2.07) | 68.6 months mean |
Progression/disease/recurrence-free survival (PFS/DFS/RFS) | |||||||||
 Cai [18] | 2017 | China | RCC | Retrospective | Target therapy | 178 | 51.62 | 1.842 (1.226–2.766) | 22 months median |
 Peng [25] | 2017 | China | BC | Retrospective | RC | 516 | 46.025/47.2 | 1.68 (1.092–2.005) | 37 months median |
 Cui [23] | 2017 | China | BC | Retrospective | TURBT | 329 | 52.57 | 1.672 (1.149–2.439) | 43.9 ± 27.1 (mean ± SD) |
 Fan [28] | 2017 | China | PC | Retrospective | Target therapy | 112 | 50.5 | 3.50 (1.10–11.0) | 20.2 months median |
 Broggi [17] | 2016 | American | RCC | Retrospective | Nephrectomy | 341 | 44.7 | 2.26 (1.42–3.73) | NR |
 Kwon [21] | 2017 | Korea | RCC | Retrospective | Target therapy | 125 | 41 | 3.33 (1.35–8.33) | 45.3 months median |
 Peng [22] | 2017 | China | RCC | Retrospective | Nephrectomy | 1360 | 47.625/47.775 | 1.705 (1.266–2.296) | 67 months median |
 Kim [27] | 2015 | Korea | UTUC | Retrospective | NU | 277 | 45 | 1.183 (0.656–2.132) | 57.2 months median |
 Jeon [20] | 2016 | Korea | RCC | Retrospective | PN, RN | 1437 | 51 | 1.47 (1.03–2.11) | 68.6 months mean |
 Hofbauer [19] | 2015 | Austria | RCC | Retrospective | PN, RN | 1344 | 48 | 1.96 (1.32–2.86) | 40 months median |
Cancer/disease-specific survival (CSS/DSS) | |||||||||
 Miyake [24] | 2017 | Japan | BC | Retrospective | RC | 117 | 50 | 3.30 (1.40–7.40) | 22 months median |
 Huang [26] | 2017 | China | UTUC | Retrospective | RNU | 425 | 46.78 | 1.98 (1.31–2.99) | 38.5 months median |
 Jeon [20] | 2016 | Korea | RCC | Retrospective | PN, RN | 1437 | 51 | 1.51 (1.05–2.19) | 68.6 months mean |
 Kim [27] | 2015 | Korea | UTUC | Retrospective | NU | 277 | 45 | 0.947 (0.491–1.826) | 57.2 months median |
 Hofbauer [19] | 2015 | Austria | RCC | Retrospective | PN, RN | 1344 | 48 | 1.49 (1.19–1.89) | 40 months median |